In this study, we have demonstrated that our findings suggest that a short-term (4-week) therapy with SGLT-2 inhibitors in T2D patients may exert multifaceted benefits on metabolic, renal, hematological, and neuropathic endpoints parallel with the changes in the hydroxyl free radical exposure. Here, SLC5A2 is linked to type 2 diabetes mellitus.